-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
-
Summary
-
Arrowhead Pharmaceuticals, Inc. quarterly/annual Depreciation, Depletion and Amortization history and growth rate from 2010 to 2024.
- Arrowhead Pharmaceuticals, Inc. Depreciation, Depletion and Amortization for the quarter ending September 30, 2024 was $4.6M, a 39.4% increase year-over-year.
- Arrowhead Pharmaceuticals, Inc. Depreciation, Depletion and Amortization for the twelve months ending September 30, 2024 was $16.9M, a 57.9% increase year-over-year.
- Arrowhead Pharmaceuticals, Inc. annual Depreciation, Depletion and Amortization for 2024 was $16.9M, a 57.9% increase from 2023.
- Arrowhead Pharmaceuticals, Inc. annual Depreciation, Depletion and Amortization for 2023 was $10.7M, a 23% increase from 2022.
- Arrowhead Pharmaceuticals, Inc. annual Depreciation, Depletion and Amortization for 2022 was $8.7M, a 31.8% increase from 2021.
Depreciation, Depletion and Amortization, Trailing 12 Months (USD)
Depreciation, Depletion and Amortization, Annual (USD)
Depreciation, Depletion and Amortization, YoY Annual Growth (%)